Close Menu

    Subscribe to Updates

    Get the latest creative news from Healthradar about News,Health and Gadgets.

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    What's Hot

    Medable Launches Agent Studio, the First Agentic AI Platform for Life Sciences

    4. September 2025

    WellSpan Health and General Catalyst Announce Partnership to Transform Healthcare Delivery

    4. September 2025

    Suri 2.0 Sustainable Sonic Toothbrush review: upgraded to clean your teeth and the planet even better

    4. September 2025
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram Pinterest Vimeo
    healthradar.nethealthradar.net
    • Home
    • Ai
    • Gadgets
    • Health
    • News
    • Contact Us
    Contact
    healthradar.nethealthradar.net
    Home»News»The First AI-Powered Tool for Prostate Cancer Prognosis –
    News

    The First AI-Powered Tool for Prostate Cancer Prognosis –

    HealthradarBy Healthradar14. August 2025Keine Kommentare2 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
    The First AI-Powered Tool for Prostate Cancer Prognosis –
    Share
    Facebook Twitter LinkedIn Pinterest Email


    FDA Authorizes ArteraAI Prostate: The First AI-Powered Tool for Prostate Cancer Prognosis

    What You Should Know:

    –  Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for ArteraAI Prostate, establishing it as the first and only AI-powered software authorized to prognosticate long-term outcomes for patients with non-metastatic prostate cancer.

    – ArteraAI Prostate is now recognized as an FDA-regulated Software as a Medical Device (SaMD).

    Artera Secures FDA De Novo Authorization for AI-Powered Prostate Cancer Diagnostic Platform

    Artera, a global leader in precision oncology, is redefining cancer care through its multimodal artificial intelligence (MMAI) platform, which integrates digitized biopsy images with patient clinical data to assess cancer aggressiveness and predict therapy benefit. Validated across multiple Phase 3 randomized trials and various cancer types, Artera’s MMAI technology is deployed globally through a suite of innovative products.

    The company’s flagship ArteraAI Prostate Test—commercially available in the U.S. as a laboratory-developed test and internationally via distribution partners—is the first test to provide both prognostic and predictive insights for prostate cancer, enabling clinicians and patients to make timely, evidence-based treatment decisions.

    Regulatory Milestone and Expanded Capabilities

    Artera has earned FDA De Novo authorization for its ArteraAI Prostate medical device software, establishing a new product code category for future AI-powered digital pathology risk-stratification tools. This authorization, paired with UKCA certification for the ArteraAI Breast Test, ArteraAI Prostate Biopsy Assay, and ArteraAI Prostate, extends the platform’s reach across key global markets.

    • Point-of-Diagnosis Integration – Enables qualified pathology labs in the U.S. to deliver actionable prostate cancer insights at the time of diagnosis, reducing delays in care.
    • Predetermined Change Control Plan – Allows platform expansion to additional digital pathology scanners without requiring new 510(k) submissions.
    • Breakthrough Device Designation – Preceded the De Novo authorization, underscoring the innovation’s clinical significance.

    “This is a defining moment for AI in cancer care,” said Andre Esteva, CEO and co-founder of Artera. “The FDA’s decision validates our vision to deliver AI-guided tools that enable data-backed, tailored treatments for each patient—enhancing confidence throughout the cancer journey and ultimately saving more lives.”

    With its latest regulatory clearance, Artera is positioned to scale its MMAI-powered portfolio, accelerating the adoption of precision oncology solutions and advancing the standard of personalized cancer care worldwide.



    Source link

    AIPowered cancer Prognosis Prostate tool
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleAltera Digital Health Delivers Ambient Listening and Note Generation to Provider Practices with TouchWorks Note+
    Next Article Amalgam Rx Secures $20M Credit Investment from Catalio Capital Management to Accelerate Medical-Grade AI™ Deployment
    ekass777x
    Healthradar
    • Website

    Related Posts

    News

    Medable Launches Agent Studio, the First Agentic AI Platform for Life Sciences

    4. September 2025
    News

    WellSpan Health and General Catalyst Announce Partnership to Transform Healthcare Delivery

    4. September 2025
    Health

    ArcaScience Raises $7M to Advance AI-Powered Drug Benefit-Risk Evaluation

    4. September 2025
    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    Garmin Venu 4: Everything we know so far about the premium smartwatch

    7. August 202560 Views

    The Top 3 Tax Mistakes High-Earning Physicians Make

    7. August 202523 Views

    Linea Expands AI-Powered Heart Failure Care Solution

    6. August 202519 Views

    Neurode wants to treat and track ADHD symptoms through a wearable headband

    1. Juni 20259 Views
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews

    Subscribe to Updates

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    About Us

    Welcome to HealthRadar.net — your trusted destination for discovering the latest innovations in digital health. We are dedicated to connecting individuals, healthcare professionals, and organizations with cutting-edge tools, applications

    Most Popular

    Garmin Venu 4: Everything we know so far about the premium smartwatch

    7. August 202560 Views

    The Top 3 Tax Mistakes High-Earning Physicians Make

    7. August 202523 Views
    USEFULL LINK
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    QUICK LINKS
    • Ai
    • Gadgets
    • Health
    • News
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    Copyright© 2025 Healthradar All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.